Other DLL3-targeting agents, such as T cell-redirecting therapies and immuno-oncology therapies (AMG 757 and AMG 119), may have a high effect and specificity for DLL3-positive SCLC tumor cells (25–27). Here, DLL3 is linked to neoplasm.